Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
74.8 USD | +0.82% | +4.31% | -6.02% |
04-30 | North American Morning Briefing : More Earnings -2- | DJ |
04-29 | Axsome Therapeutics Phase 3 Alzheimer's Treatment Trial is High Risk, High Reward, Morgan Stanley Says | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-6.02% | 3.55B | |
-3.79% | 88.14B | |
+1.45% | 40.51B | |
-15.94% | 31.67B | |
+52.66% | 24.62B | |
-14.50% | 15.65B | |
-14.38% | 12.07B | |
-9.12% | 11.97B | |
-42.56% | 11.61B | |
+4.87% | 8.81B |
- Stock Market
- Equities
- AXSM Stock
- News Axsome Therapeutics, Inc.
- Axsome Therapeutics : Launches Phase 3 Trial of AXS-05 in Patients With Alzheimer's Disease Agitation